A part of Watch Media

MedWatchSunday5 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
22/08/2022at 08:43

Coloplast struggles to meet demand due to silicone shortage

The Danish medtech company can’t source adequate amounts of the silicone required for uridome catheter products, affecting Coloplast’s continence business.
Photo: Coloplast / PR
by ulrich quistgaard, translated by daniel pedersen

A global raw materials shortage is affecting Coloplast’s Continence Care business, which can no longer support demand for the company’s uridome catheter products, which are used to collect urine.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Coloplast / PR

    Coloplast presents strong Q3 figures

    For subscribers

  • Photo: Ambu / PR

    Analyst: Ambu's unsightly downgrade is tied to unmet growth expectations

    For subscribers

  • Photo: Coloplast / PR

    Coloplast postpones launch of ostomy care platform

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.
  • Novo Nordisk declared world's best place to work in 2022
  • Novo Nordisk meets upgraded guidance, sets new revenue record

For subscribers

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Further reading

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

The Danish medtech company hopes to win market shares with a new product, Luja, heralding it a ”growth driver within continence care.”

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Application Manager

  • Commercial Director

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Application Manager

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Supply Chain Manager

See all jobs

Jobs

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Sr. Director, Drug Safety Physician

  • Senior Clinical Project Manager

  • Medical Advisor (Metabolism)

  • Application Manager

  • Commercial Director

  • Senior Health Economics and Outcomes Research (HEOR) Manager

  • Clinical Operational Associate

  • Application Manager

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Supply Chain Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge